{"entity":"abbvie","id":"ent_abbvie","name":"AbbVie","wikidata":"Q14662364","page":"https://asof.is/record/abbvie","summary":"As of November 12, 2025, AbbVie was a pharmaceutical company, headquartered in North Chicago and founded in 2012. Its CEO was Robert A. Michael, since 2024. It reported revenue of $56.33B for the period ended December 31, 2024.","title":"AbbVie: CEO Robert A. Michael, revenue $56.33B","key_facts":[{"label":"CEO","value":"Robert A. Michael","note":"since 2024","claim":"clm_5B7824F67B5A"},{"label":"CFO","value":"Scott T. Reents","claim":"clm_5E1BA5E19048"},{"label":"Headquarters","value":"North Chicago","claim":"clm_E74DBC8CCF1E"},{"label":"Founded","value":"2012","recorded":"2012-04-10","claim":"clm_141AEBE438E4"},{"label":"Revenue","value":"$56.33B","recorded":"56,334,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_46C087CADCC6"},{"label":"Ticker","value":"ABBV · NYSE","claim":"clm_B87EDEAECF6B"}],"faq":[{"question":"Who is the CEO of AbbVie?","answer":"Robert A. Michael, since 2024, as the AsOf record states with its sources."},{"question":"Where is AbbVie headquartered?","answer":"North Chicago."},{"question":"When was AbbVie founded?","answer":"In 2012."},{"question":"What is AbbVie's revenue?","answer":"$56.33B for the period ended December 31, 2024."}],"as_of":"2025-11-12","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/abbvie/ceo","md":"https://asof.is/record/abbvie/ceo.md","json":"https://asof.is/v1/entities/abbvie/ceo"},{"predicate":"cfo","page":"https://asof.is/record/abbvie/cfo","md":"https://asof.is/record/abbvie/cfo.md","json":"https://asof.is/v1/entities/abbvie/cfo"},{"predicate":"coo","page":"https://asof.is/record/abbvie/coo","md":"https://asof.is/record/abbvie/coo.md","json":"https://asof.is/v1/entities/abbvie/coo"},{"predicate":"president","page":"https://asof.is/record/abbvie/president","md":"https://asof.is/record/abbvie/president.md","json":"https://asof.is/v1/entities/abbvie/president"},{"predicate":"board_member","page":"https://asof.is/record/abbvie/board_member","md":"https://asof.is/record/abbvie/board_member.md","json":"https://asof.is/v1/entities/abbvie/board_member"},{"predicate":"headquarters","page":"https://asof.is/record/abbvie/headquarters","md":"https://asof.is/record/abbvie/headquarters.md","json":"https://asof.is/v1/entities/abbvie/headquarters"},{"predicate":"founded","page":"https://asof.is/record/abbvie/founded","md":"https://asof.is/record/abbvie/founded.md","json":"https://asof.is/v1/entities/abbvie/founded"},{"predicate":"revenue","page":"https://asof.is/record/abbvie/revenue","md":"https://asof.is/record/abbvie/revenue.md","json":"https://asof.is/v1/entities/abbvie/revenue"},{"predicate":"net_income","page":"https://asof.is/record/abbvie/net_income","md":"https://asof.is/record/abbvie/net_income.md","json":"https://asof.is/v1/entities/abbvie/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/abbvie/operating_income","md":"https://asof.is/record/abbvie/operating_income.md","json":"https://asof.is/v1/entities/abbvie/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/abbvie/quarterly_revenue","md":"https://asof.is/record/abbvie/quarterly_revenue.md","json":"https://asof.is/v1/entities/abbvie/quarterly_revenue"}],"products":[],"coverage":{"entity":"abbvie","name":"AbbVie","kind":"organization","sources":[{"source":"wikidata","item":"Q14662364","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":1551152,"ticker":"ABBV","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":409,"open":25,"retracted":0,"first":"2010-12-31","predicates":{"total_equity":{"claims":56,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":34,"open":1,"kind":"fact"},"total_assets":{"claims":56,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":45,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":61,"open":1,"kind":"fact"},"shares_outstanding":{"claims":55,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":45,"open":1,"kind":"fact"},"net_income":{"claims":12,"open":1,"kind":"fact"},"revenue":{"claims":15,"open":1,"kind":"fact"},"founded":{"claims":1,"open":1,"kind":"fact"},"board_member":{"claims":4,"open":4,"kind":"list"},"operating_income":{"claims":15,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"ceo":{"claims":1,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":403,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":6,"last_added":"2026-11-08","last_checked":"2026-11-10","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_3FF30F20CF7D","predicate":"board_member","value":"Robert A. Michael","valid_from":"2024-07-01","valid_to":null,"published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie board member: Robert A. Michael\", as of 2024-07-01. Claim clm_3FF30F20CF7D, https://asof.is/claim/clm_3FF30F20CF7D, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465924058808/0001104659-24-058808-index.htm.","url":"https://asof.is/claim/clm_3FF30F20CF7D","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924058808/0001104659-24-058808-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2024-05-08T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2024-02-20T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_ex99-1.htm","tier":"primary","publisher":null,"published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"selected Robert A. Michael to succeed Richard A. Gonzalez as AbbVie’s Chief Executive Officer (CEO), effective July 1, 2024 (the “Effective Date”). Upon the Effective Date, Mr. Michael will become a member of the Board as a Class II director","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924058808/0001104659-24-058808-index.htm"}},{"id":"clm_165A9874E444","predicate":"board_member","value":"Jennifer L. Davis","valid_from":"2023-10-11","valid_to":"2026-11-02","published":"2023-10-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie board member: Jennifer L. Davis\", as of 2023-10-11 (until 2026-11-02). Claim clm_165A9874E444, https://asof.is/claim/clm_165A9874E444, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm.","url":"https://asof.is/claim/clm_165A9874E444","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm","tier":"primary","publisher":null,"published_at":"2023-10-12T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926121322/0001104659-26-121322-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2026-11-02T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/0001104659-23-108864-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-10-12T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"On October 11, 2023, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from eleven directors to thirteen directors and appointed Jennifer Davis as a Class II director and Susan Quaggin as a Class III director.","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm"}},{"id":"clm_7402240BD8F8","predicate":"board_member","value":"Susan Quaggin","valid_from":"2023-10-11","valid_to":null,"published":"2023-10-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie board member: Susan Quaggin\", as of 2023-10-11. Claim clm_7402240BD8F8, https://asof.is/claim/clm_7402240BD8F8, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm.","url":"https://asof.is/claim/clm_7402240BD8F8","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm","tier":"primary","publisher":null,"published_at":"2023-10-12T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/0001104659-23-108864-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-10-12T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"On October 11, 2023, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from eleven directors to thirteen directors and appointed Jennifer Davis as a Class II director and Susan Quaggin as a Class III director.","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm"}},{"id":"clm_B5ABA873B1E0","predicate":"board_member","value":"Edward J. Rapp","valid_from":"2013-01-01","valid_to":null,"published":"2013-01-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie board member: Edward J. Rapp\", as of 2013-01-01. Claim clm_B5ABA873B1E0, https://asof.is/claim/clm_B5ABA873B1E0, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000104746913000017/a2212291z8-k.htm.","url":"https://asof.is/claim/clm_B5ABA873B1E0","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000104746913000017/a2212291z8-k.htm","tier":"primary","publisher":null,"published_at":"2013-01-02T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Each of Richard A. Gonzalez, the Chairman and Chief Executive Officer of AbbVie, Robert J. Alpern, M.D., Roxanne S. Austin, William H.L. Burnside, Edward M. Liddy, Edward J. Rapp, Roy S. Roberts, and Glenn F. Tilton were elected as a director of AbbVie, effective as of immediately prior to the Effec","url":"https://www.sec.gov/Archives/edgar/data/1551152/000104746913000017/a2212291z8-k.htm"}},{"id":"clm_E498EA77B417","predicate":"cash_and_equivalents","value":"5,629,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 5,629,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E498EA77B417, https://asof.is/claim/clm_E498EA77B417, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E498EA77B417","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F526599F9FFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_5B7824F67B5A","predicate":"ceo","value":"Robert A. Michael","valid_from":"2024-07-01","valid_to":null,"published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie ceo: Robert A. Michael\", as of 2024-07-01. Claim clm_5B7824F67B5A, https://asof.is/claim/clm_5B7824F67B5A, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465924058808/0001104659-24-058808-index.htm.","url":"https://asof.is/claim/clm_5B7824F67B5A","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924058808/0001104659-24-058808-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2024-05-08T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2024-02-20T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-23T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_ex99-1.htm","tier":"primary","publisher":null,"published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer - Richard A. Gonzalez to retire as AbbVie CEO to become executive chairman - Transition will occur on July 1, 2024","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_ex99-1.htm"}},{"id":"clm_5E1BA5E19048","predicate":"cfo","value":"Scott T. Reents","valid_from":null,"undated":true,"valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cfo: Scott T. Reents\", undated. Claim clm_5E1BA5E19048, https://asof.is/claim/clm_5E1BA5E19048, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm.","url":"https://asof.is/claim/clm_5E1BA5E19048","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Scott T. Reents 58 Executive Vice President, Chief Financial Officer","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm"}},{"id":"clm_CD48BB22552C","predicate":"cik","value":"0001551152","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cik: 0001551152\", undated. Claim clm_CD48BB22552C, https://asof.is/claim/clm_CD48BB22552C, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_CD48BB22552C","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_392093FAED2B","predicate":"coo","value":"Robert A. Michael","valid_from":"2023-06-29","valid_to":null,"published":"2023-06-29","recorded":"2026-11-12","citation":{"plain":"AsOf. \"AbbVie coo: Robert A. Michael\", as of 2023-06-29. Claim clm_392093FAED2B, https://asof.is/claim/clm_392093FAED2B, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465923076373/0001104659-23-076373-index.htm.","url":"https://asof.is/claim/clm_392093FAED2B","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923076373/0001104659-23-076373-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-06-29T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"Effective June 29, 2023, Robert A. Michael has been appointed President and Chief Operating Officer.","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923076373/0001104659-23-076373-index.htm"}},{"id":"clm_D5837D9B7367","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie fiscal year end: 12-31\", undated. Claim clm_D5837D9B7367, https://asof.is/claim/clm_D5837D9B7367, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_D5837D9B7367","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_141AEBE438E4","predicate":"founded","value":"2012-04-10","valid_from":"2012-04-10","valid_to":null,"published":"2014-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie founded: 2012-04-10\", as of 2012-04-10. Claim clm_141AEBE438E4, https://asof.is/claim/clm_141AEBE438E4, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/0001551152/000104746914001154/a2217723z10-k.htm.","url":"https://asof.is/claim/clm_141AEBE438E4","accessed":"2026-11-12"},"confidence":0.6,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/0001551152/000104746914001154/a2217723z10-k.htm","tier":"primary","publisher":"sec.gov","published_at":"2014-02-21T00:00:00+00:00"},{"url":"https://www.wikidata.org/wiki/Q14662364","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://search.gleif.org/#/record/FR5LCKFTG8054YNNRU85","tier":"secondary","publisher":null,"published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"AbbVie was incorporated in Delaware on April 10, 2012 to hold Abbott's former research-based pharmaceuticals business.","url":"https://www.sec.gov/Archives/edgar/data/0001551152/000104746914001154/a2217723z10-k.htm"}},{"id":"clm_E74DBC8CCF1E","predicate":"headquarters","value":"North Chicago","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie headquarters: North Chicago\", undated. Claim clm_E74DBC8CCF1E, https://asof.is/claim/clm_E74DBC8CCF1E, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_E74DBC8CCF1E","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_BBC331549951","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie listed on: NYSE\", undated. Claim clm_BBC331549951, https://asof.is/claim/clm_BBC331549951, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_BBC331549951","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4595D4B200E2","predicate":"net_income","value":"4,278,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,278,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4595D4B200E2, https://asof.is/claim/clm_4595D4B200E2, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_4595D4B200E2","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A3E6A20A337","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_7198B453007F","predicate":"operating_income","value":"9,137,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 9,137,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_7198B453007F, https://asof.is/claim/clm_7198B453007F, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_7198B453007F","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D4AF640165D7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_4A0FE32EBE69","predicate":"president","value":"Robert A. Michael","valid_from":"2023-06-29","valid_to":null,"published":"2023-06-29","recorded":"2026-11-12","citation":{"plain":"AsOf. \"AbbVie president: Robert A. Michael\", as of 2023-06-29. Claim clm_4A0FE32EBE69, https://asof.is/claim/clm_4A0FE32EBE69, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000110465923076373/0001104659-23-076373-index.htm.","url":"https://asof.is/claim/clm_4A0FE32EBE69","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923076373/0001104659-23-076373-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-06-29T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"Effective June 29, 2023, Robert A. Michael has been appointed President and Chief Operating Officer.","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923076373/0001104659-23-076373-index.htm"}},{"id":"clm_48C26099DBC0","predicate":"quarterly_net_income","value":"186,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 186,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_48C26099DBC0, https://asof.is/claim/clm_48C26099DBC0, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_48C26099DBC0","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_879DEDC1ACEA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_8A7602897846","predicate":"quarterly_operating_income","value":"1,904,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 1,904,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8A7602897846, https://asof.is/claim/clm_8A7602897846, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_8A7602897846","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78F42A193166","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_7673BF825A9D","predicate":"quarterly_revenue","value":"15,776,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 15,776,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7673BF825A9D, https://asof.is/claim/clm_7673BF825A9D, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_7673BF825A9D","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2A1D46B6132E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_78F47A4D8706","predicate":"registrant_name","value":"AbbVie Inc.","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie registrant name: AbbVie Inc.\", undated. Claim clm_78F47A4D8706, https://asof.is/claim/clm_78F47A4D8706, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_78F47A4D8706","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_46C087CADCC6","predicate":"revenue","value":"56,334,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 56,334,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_46C087CADCC6, https://asof.is/claim/clm_46C087CADCC6, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm.","url":"https://asof.is/claim/clm_46C087CADCC6","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4A7BE8ED0078","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/0001551152-25-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-14"}},{"id":"clm_A66CE3EA88E8","predicate":"shares_outstanding","value":"1,767,384,632 shares","valid_from":"2025-10-27","valid_to":"2026-02-10","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,384,632 shares\", as of 2025-10-27 (until 2026-02-10). Claim clm_A66CE3EA88E8, https://asof.is/claim/clm_A66CE3EA88E8, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_A66CE3EA88E8","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F33386E6A71F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_60D3FAD20B06","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_60D3FAD20B06, https://asof.is/claim/clm_60D3FAD20B06, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_60D3FAD20B06","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_50468CC9D02A","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie state of incorporation: DE\", undated. Claim clm_50468CC9D02A, https://asof.is/claim/clm_50468CC9D02A, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_50468CC9D02A","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B87EDEAECF6B","predicate":"ticker","value":"ABBV","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie ticker: ABBV\", undated. Claim clm_B87EDEAECF6B, https://asof.is/claim/clm_B87EDEAECF6B, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_B87EDEAECF6B","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_9AD5C074902A","predicate":"total_assets","value":"133,898,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 133,898,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_9AD5C074902A, https://asof.is/claim/clm_9AD5C074902A, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_9AD5C074902A","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BAF68C4E73F9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_E6BEEAB8A7CC","predicate":"total_equity","value":"-2,642,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -2,642,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_E6BEEAB8A7CC, https://asof.is/claim/clm_E6BEEAB8A7CC, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm.","url":"https://asof.is/claim/clm_E6BEEAB8A7CC","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A970AB08DB3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing"}}}